CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis

Blood. 2012 Sep 6;120(10):2055-63. doi: 10.1182/blood-2012-03-416792. Epub 2012 Jun 15.

Abstract

The transfer of membrane proteins between cells during contact, known as trogocytosis, can create novel cells with a unique phenotype and altered function. We demonstrate that trogocytosis is more common in multiple myeloma (MM) than chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia; that T cells are more probable to be recipients than B or natural killer cells; that trogocytosis occurs independently of either the T-cell receptor or HLA compatibility; and that after trogocytosis, T cells with acquired antigens can become novel regulators of T-cell proliferation. We screened 168 patients with MM and found that CD86 and human leukocyte antigen G (HLA-G) were antigens commonly acquired by T cells from malignant plasma cells. CD3+ CD86acq+ and CD3+ HLA-Gacq+ cells were more prevalent in bone marrow than peripheral blood samples. The presence of either CD86 or HLA-G on malignant plasma cells was associated with a poor prognosis. CD38++ side population cells expressed HLA-G, suggesting that these putative myeloma stem cells could generate immune tolerance. HLA-G+ T cells had a regulatory potency similar to natural Tregs, thus providing another novel mechanism for MM to avoid effective immune surveillance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism
  • B7-2 Antigen / immunology*
  • Biomarkers / analysis
  • Cell Membrane / immunology
  • Cell Membrane / metabolism
  • Cell Proliferation
  • HLA-G Antigens / immunology*
  • Humans
  • Immune Tolerance
  • Killer Cells, Natural / immunology
  • Killer Cells, Natural / metabolism
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Multiple Myeloma / immunology
  • Multiple Myeloma / metabolism*
  • Multiple Myeloma / mortality
  • Organ Specificity
  • Plasma Cells / immunology*
  • Plasma Cells / metabolism
  • Prognosis
  • Protein Transport / immunology
  • Survival Rate
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • Waldenstrom Macroglobulinemia / immunology
  • Waldenstrom Macroglobulinemia / metabolism*
  • Waldenstrom Macroglobulinemia / mortality

Substances

  • B7-2 Antigen
  • Biomarkers
  • HLA-G Antigens